Literature DB >> 25859380

Fanconi syndrome with lysinuric protein intolerance.

Eleonora Riccio1, Antonio Pisani1.   

Abstract

We present the case of a 9-year-old child with lysinuric protein intolerance and Fanconi syndrome. She was referred to our hospital with a persistent metabolic acidosis and polyuria. Renal investigations revealed all laboratory signs of Fanconi syndrome, with glucosuria, generalized aminoaciduria, phosphaturia and severe hypercalciuria. The diagnosis of Fanconi syndrome was confirmed by a renal biopsy that showed extensive lesions of proximal tubular epithelial cells with vacuolation of these cells and a sloughing of the brush border.

Entities:  

Keywords:  Fanconi syndrome; hyperammonaemia; lysinuric protein intolerance

Year:  2014        PMID: 25859380      PMCID: PMC4389143          DOI: 10.1093/ckj/sfu107

Source DB:  PubMed          Journal:  Clin Kidney J        ISSN: 2048-8505


Introduction

Lysinuric protein intolerance (LPI; OMIM 222700) is a rare autosomal recessive multiorgan disorder in which the renal and intestinal transport of the cationic amino acids lysine, arginine and ornithine is defective [1]. The molecular defect resides in mutations of the SLC7A7 gene, encoding for y+ LAT-1, the catalytic light chain subunit of a complex belonging to the heterodimeric amino acid transporter family [2]. The basolateral transport defect is expressed in the epithelial cells of the intestine and the kidney tubules, hepatocytes and skin fibroblasts [3], leading to a depletion of their tissue pools and, as a consequence, to impaired functioning of the hepatic urea cycle with hyperammonaemic episodes (Figure 1). Most, but not all, of the symptoms of LPI have been linked to a secondary urea cycle derangement due to impaired transport of cationic amino acids. Typically, symptoms begin after weaning with refusal of feeding, vomiting and consequent failure to thrive. Hepatosplenomegaly, haematological anomalies and neurological involvement, including hyperammonaemic coma, are recurrent clinical features [4, 5]. Two major complications, pulmonary alveolar proteinosis and renal disease, are increasingly observed in LPI patients [5, 6]. The disease has long been erroneously considered relatively benign when appropriately treated with low-protein diet and l-citrulline supplementation. During the past years, however, other manifestations have suggested that LPI is not only a urea cycle disorder, but also a complex multisystem disease with an uncertain outcome [7], thus considerably modifying the way to view this disorder.
Fig. 1.

Pathway for the disposal of nitrogen waste products in the urea cycle. Each number represents the following enzymes: 1, carbamylphosphate synthetase; 2, ornithine carbamyltransferase; 3, argininosuccinate synthetase; 4, argininosuccinate lyase; 5, arginase; 6, N-acetylglutamate synthetase. CoA, co-enzyme A; NH3, ammonia.

Pathway for the disposal of nitrogen waste products in the urea cycle. Each number represents the following enzymes: 1, carbamylphosphate synthetase; 2, ornithine carbamyltransferase; 3, argininosuccinate synthetase; 4, argininosuccinate lyase; 5, arginase; 6, N-acetylglutamate synthetase. CoA, co-enzyme A; NH3, ammonia. We describe the clinical course in a patient with LPI and renal pathology.

Case report

The patient was diagnosed with LPI at the 7 years of age; she was born to consanguineous (first-cousin) healthy parents after three abortions. The patient had a brother who died at the age of 6 years of respiratory failure; he was diagnosed with mucopolysaccharidosis because of the findings of delayed psychomotor development, anorexia, repeated episodes of acute bronchitis, hepatosplenomegaly and pancytopenia. At 6 years, our patient presented signs and symptoms similar to those observed in her brother: in particular, she was hospitalized because of delayed psychomotor development, vomiting and mild hepatosplenomegaly. The family history and clinical features suggested a diagnosis of metabolic disease that was then investigated. Complete blood count showed that mild pancytopenia, renal and hepatic functions were normal, lactate was 2.5 mmol/L (normal <2 mmol/L), plasma ammonia was 194 mmol/L (normal <70 mmol/L), ferritin was 103 mmol/L (normal 2–59 mmol/L) and LDH was 1180 U/L (normal 26–534 U/L). LPI was diagnosed based on the findings of reduced plasma ornithine, arginine and lysine, and of an increase in their urinary levels. The final proof of a defect in the SLC7A7 amino acid transporter was given by the finding of a homozygous c.726G>A mutation in the patient's DNA [8], responsible for the premature termination of the protein at aminoacid 242. Subsequently, she was put on a protein-restricted diet (0.7–1.2 g/kg per day) and l-citrulline supplementation (100 mg/kg per day), and in the following 2 years her clinical condition remained stable and the plasma ammonia levels were in the normal range. Then, at the age of 9, a persistent metabolic acidosis (pH 7.33, pCO2 28 mmHg and bicarbonate 14 mmol/L) with an elevated anion gap of 20.4 (normal <15) was observed, and the patient was referred to our hospital. Plasma organic acids were normal. Furthermore, the patient presented polyuria (diuresis >3000 mL/day) and renal investigations revealed all laboratory signs of Fanconi syndrome, with glucosuria, generalized aminoaciduria, phosphaturia and severe hypercalciuria (Table 1). The glomerular filtration rate, evaluated by the creatinine clearance (Schwartz equation), was 88 mL/min per 1.73 m2 (normal 80–120). Echosonography of the kidney was normal.
Table 1.

Laboratory data on admission

Normal rangePatient
Serum potassium (mEq/L)3.6–5.03.3
Serum phosphorus (mg/dL)2.5–4.32.6
Serum uric acid (mg/dL)2.5–7.52.1
Serum chloride (mEq/L)101–10983
Serum bicarbonate (mmol/L)22.0–26.014
Anion gap (mEq/L)12 ± 320.4
ProteinuriaNegative (−)(+)
Urinary pH4.8–7.56.5
Urinary glucoseNegative (−)(3+)
Laboratory data on admission To explain the combination of a renal Fanconi syndrome and elevated levels of organic acids in the urine, a renal biopsy was performed after parental informed consent had been obtained. Consistent with the existence of a Fanconi syndrome, renal biopsy showed extensive lesions of proximal tubular epithelial cells with a dramatic vacuolation of these cells and a sloughing of the brush border. No evidence of immune deposits was shown by immunofluorescence (Figure 2).
Fig. 2.

Light microscopy shows proximal tubules with vacuolated cytoplasm and brush border attenuation.

Light microscopy shows proximal tubules with vacuolated cytoplasm and brush border attenuation.

Discussion

Renal involvement is a well-known manifestation of LPI. However, its progressive characteristic has recently been emphasized [9]. Most of the patients present with mild proteinuria and microscopic haematuria for years without overt consequences. However, some patients have glomerular dysfunction due to mild glomerulonephritis, whereas others display signs of Fanconi syndrome [9, 10]. Renal involvement may sometimes progress to end-stage renal disease requiring dialysis and renal transplantation [9]. Our patient had evidence of a full-blown Fanconi syndrome with proximal tubular acidosis. Besides a proximal tubular acidosis, other signs of a complex tubular disorder were found, i.e. diminished renal reabsorption of phosphate [11], glucose, amino acids and carnitine. The majority of cases of proximal renal tubular acidosis fit into the category of generalized tubule dysfunction with the Fanconi syndrome. This defect can be due either to backleak of solutes via the paracellular pathway or to a generalized disorder of the apical membrane and its transporters, a disorder of the basolateral Na+, K+-ATPase or a metabolic disorder that lowers ATP concentration. Electron microscopy of renal tissue showed severe abnormalities in the ultrastructure of proximal tubular apical membranes. We suggest that this is the basic disorder causing proximal tubular dysfunction, either through a diminished resorptive area and decreased availability of transport proteins or through increased backleak of solutes from the proximal tubular cell. The cause of the ultrastructural changes remains to be determined; possible mechanisms are a direct toxic effect of retained metabolites on the cell membrane or a generalized disorder in cellular energy metabolism [5]. The hypothesis that the accumulation of intracellular lysine in the proximal tubule because of diminished basolateral transport might exercise a cytotoxic effect leading to renal tubular damage [12] has been confuted by the evidence that patients with hyperlysinaemia due to other diseases (i.e. 2-aminoadipic semialdehyde synthetase deficiency), with a similar heavy load on the renal tubular y+ LAT-1 system, never develop a renal Fanconi syndrome [13]. Therefore, we consider the intratubular accumulation of lysine an unlikely candidate for the development of the renal Fanconi syndrome. It is known that, in LPI, there is a specific defect of dibasic aminoacid transport, located at the basolateral membrane of epithelial cells. However, this defect does not cause disturbances in other basolateral transport systems, such as Na+ and K+-ATPase. It is therefore not likely that it would be the cause of the Fanconi syndrome. In conclusion, this case demonstrates a rapid development of a Fanconi syndrome in a child with LPI. The existence and possible cytotoxic effect of intracellular lysine accumulation in proximal tubular cells deserve further attention.

Conflict of interest statement

None declared.
  12 in total

1.  Functional analysis of novel mutations in y(+)LAT-1 amino acid transporter gene causing lysinuric protein intolerance (LPI).

Authors:  J Mykkänen; D Torrents; M Pineda; M Camps; M E Yoldi; N Horelli-Kuitunen; K Huoponen; M Heinonen; J Oksanen; O Simell; M L Savontaus; A Zorzano; M Palacín; P Aula
Journal:  Hum Mol Genet       Date:  2000-02-12       Impact factor: 6.150

2.  Lysinuric protein intolerance: one gene, many problems.

Authors:  Stefan Bröer
Journal:  Am J Physiol Cell Physiol       Date:  2007-05-02       Impact factor: 4.249

3.  Mechanisms of lysine-induced acute renal failure in rats.

Authors:  L C Racusen; W F Finn; A Whelton; K Solez
Journal:  Kidney Int       Date:  1985-03       Impact factor: 10.612

4.  Basolateral-membrane transport defect for lysine in lysinuric protein intolerance.

Authors:  J Rajantie; O Simell; J Perheentupa
Journal:  Lancet       Date:  1980-06-07       Impact factor: 79.321

5.  Lysinuric protein intolerance presenting as childhood osteoporosis. Clinical and skeletal response to citrulline therapy.

Authors:  T O Carpenter; H L Levy; M E Holtrop; V E Shih; C S Anast
Journal:  N Engl J Med       Date:  1985-01-31       Impact factor: 91.245

6.  Protein intolerance with deficient transport of basic aminoacids. Another inborn error of metabolism.

Authors:  J Perheentupa; J K Visakorpi
Journal:  Lancet       Date:  1965-10-23       Impact factor: 79.321

7.  Identification of SLC7A7, encoding y+LAT-1, as the lysinuric protein intolerance gene.

Authors:  D Torrents; J Mykkänen; M Pineda; L Feliubadaló; R Estévez; R de Cid; P Sanjurjo; A Zorzano; V Nunes; K Huoponen; A Reinikainen; O Simell; M L Savontaus; P Aula; M Palacín
Journal:  Nat Genet       Date:  1999-03       Impact factor: 38.330

8.  Pulmonary alveolar proteinosis and glomerulonephritis in lysinuric protein intolerance: case reports and autopsy findings of four pediatric patients.

Authors:  K Parto; M Kallajoki; H Aho; O Simell
Journal:  Hum Pathol       Date:  1994-04       Impact factor: 3.466

9.  Nephropathy advancing to end-stage renal disease: a novel complication of lysinuric protein intolerance.

Authors:  Laura M Tanner; Kirsti Näntö-Salonen; Harri Niinikoski; Timo Jahnukainen; Päivi Keskinen; Heikki Saha; Kristiina Kananen; Antero Helanterä; Martti Metso; Marjatta Linnanvuo; Kirsi Huoponen; Olli Simell
Journal:  J Pediatr       Date:  2007-06       Impact factor: 4.406

10.  Renal Fanconi syndrome with ultrastructural defects in lysinuric protein intolerance.

Authors:  M A Benninga; M Lilien; T J de Koning; M Duran; F G A Versteegh; R Goldschmeding; B T Poll-The
Journal:  J Inherit Metab Dis       Date:  2007-05-19       Impact factor: 4.982

View more
  3 in total

1.  A global Slc7a7 knockout mouse model demonstrates characteristic phenotypes of human lysinuric protein intolerance.

Authors:  Bridget M Stroup; Ronit Marom; Xiaohui Li; Chih-Wei Hsu; Cheng-Yen Chang; Luan D Truong; Brian Dawson; Ingo Grafe; Yuqing Chen; Ming-Ming Jiang; Denise Lanza; Jennie Rose Green; Qin Sun; J P Barrish; Safa Ani; Audrey E Christiansen; John R Seavitt; Mary E Dickinson; Farrah Kheradmand; Jason D Heaney; Brendan Lee; Lindsay C Burrage
Journal:  Hum Mol Genet       Date:  2020-08-03       Impact factor: 6.150

Review 2.  Overview of symptoms and treatment for lysinuric protein intolerance.

Authors:  Atsuko Noguchi; Tsutomu Takahashi
Journal:  J Hum Genet       Date:  2019-06-18       Impact factor: 3.172

3.  Immune Dysregulation Mimicking Systemic Lupus Erythematosus in a Patient With Lysinuric Protein Intolerance: Case Report and Review of the Literature.

Authors:  Josefina Longeri Contreras; Mabel A Ladino; Katherine Aránguiz; Gonzalo P Mendez; Zeynep Coban-Akdemir; Bo Yuan; Richard A Gibbs; Lindsay C Burrage; James R Lupski; Ivan K Chinn; Tiphanie P Vogel; Jordan S Orange; M Cecilia Poli
Journal:  Front Pediatr       Date:  2021-05-20       Impact factor: 3.418

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.